EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Dupilumab therapy in atopic dermatitis when cutaneous lymphoma is suspected: Consensus recommendations from the EORTC Cutaneous Lymphoma Tumour Group

Joana Calvão, Adèle de Masson, Antonio Cozzio, Chalid Assaf, Constanze Jonak, Emmilia Hodak, Evangelia Papadavid, Gabriele Roccuzzo, Jan Peter Nicolay, Julia Scarisbrick, Maarten H Vermeer, Martine Bagot und 9 weitere

Journal of Allergy and Clinical Immunology · 2026-06 · 157 (6) · 1237-1245

DOI: 10.1016/j.jaci.2026.04.002 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Allergy and Clinical Immunology, 2026-06. Verfasst von Joana Calvão und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Coimbra University Hospital, Local Health Unit of Coimbra, Coimbra, Portugal; Faculty of Medicine, University of Coimbra, …. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized, Lymphoma, T-Cell, Cutaneous, Skin Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dupilumab is highly effective for moderate-to-severe atopic dermatitis (AD). Increasing reports of cutaneous T-cell lymphoma (CTCL) diagnosed during or after dupilumab therapy have raised concern, although a causal relationship remains unproven. Interpretation of the available evidence is limited by its retrospective, observational nature, diagnostic overlap between AD and early CTCL, and detection and surveillance bias. These clinical consensus recommendations, developed through expert consensus among European CTCL specialists, primarily address dupilumab receipt in patients initially diagnosed with AD in whom CTCL is suspected, while briefly considering selective IL-13 inhibitors for which evidence remains limited. Clinical, epidemiologic, and mechanistic evidence is synthesized to develop practice-oriented recommendations. Dupilumab remains an appropriate treatment for moderate-to-severe AD but should be avoided if mycosis fungoides or Sézary syndrome is suspected or confirmed. In atypical or treatment-refractory disease, particularly adult-onset AD without atopic history, clinicians should maintain a high index of suspicion for CTCL, with a low threshold for skin biopsy, clinicopathologic correlation, and T-cell clonality assessment. Lack of response, disease worsening, or emerging atypical features during therapy should prompt reassessment. These recommendations reflect expert consensus that is based on available evidence and highlight the need for prospective studies to better define risk profiles and guide patient selection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAntibodies, Monoclonal, HumanizedLymphoma, T-Cell, CutaneousSkin NeoplasmsHumans

Stichwörter der Autor:innen

DupilumabSézary syndromeatopic dermatitisbiologic therapyconsensus recommendationscutaneous T-cell lymphomadiagnostic delaymycosis fungoides

Substanzen

dupilumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Dermatology, Coimbra University Hospital, Local Health Unit of Coimbra, Coimbra, Portugal; Faculty of Medicine, University of Coimbra, Coimbra, Portugal.
  • Department of Dermatology, Saint Louis Hospital, Université Paris Cité, Institut National de la Santé et de la Recherche Médicale (INSERM) U1342, Paris, France.
  • Division of Dermatology, Venereology and Allergology, HOCH Cantonal Hospital St Gallen, St Gallen, Switzerland.
  • Department of Dermatology, Helios Klinikum Krefeld, Health and Medical University, Düsseldorf-Krefeld, Germany.
  • Department of Dermatology, Medical University of Vienna, Vienna, Austria.
  • Cutaneous Lymphoma Service, Davidoff Cancer Centre, Rabin Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Gray Faculty of Medicinal and Health Sciences, Tel Aviv University, Tel Aviv,…

Zitieren

APA

Calvão, J., de Masson, A., Cozzio, A., Assaf, C., Jonak, C., Hodak, E., Papadavid, E., Roccuzzo, G., Nicolay, J. P., Scarisbrick, J., Vermeer, M. H., Bagot, M., Battistella, M., Ortiz-Romero, P. L., Brunner, P., Quaglino, P., Cowan, R., Stadler, R., Kempf, W., …, & Guenova, E. (2026). Dupilumab therapy in atopic dermatitis when cutaneous lymphoma is suspected: Consensus recommendations from the EORTC Cutaneous Lymphoma Tumour Group. Journal of Allergy and Clinical Immunology, 157(6), 1237-1245. https://doi.org/10.1016/j.jaci.2026.04.002

Vancouver

Calvão J, de Masson A, Cozzio A, Assaf C, Jonak C, Hodak E, et al. Dupilumab therapy in atopic dermatitis when cutaneous lymphoma is suspected: Consensus recommendations from the EORTC Cutaneous Lymphoma Tumour Group. Journal of Allergy and Clinical Immunology. 2026;157(6):1237-1245. doi:10.1016/j.jaci.2026.04.002

BibTeX
@article{Calvo2026,
  author = {Calvão, Joana and de Masson, Adèle and Cozzio, Antonio and Assaf, Chalid and Jonak, Constanze and Hodak, Emmilia and Papadavid, Evangelia and Roccuzzo, Gabriele and Nicolay, Jan Peter and Scarisbrick, Julia and Vermeer, Maarten H and Bagot, Martine and Battistella, Maxime and Ortiz-Romero, Pablo Luis and Brunner, Patrick and Quaglino, Pietro and Cowan, Richard and Stadler, Rudolf and Kempf, Werner and Gonçalo, Margarida and Guenova, Emmanuella},
  title = {Dupilumab therapy in atopic dermatitis when cutaneous lymphoma is suspected: Consensus recommendations from the EORTC Cutaneous Lymphoma Tumour Group},
  journal = {Journal of Allergy and Clinical Immunology},
  year = {2026},
  volume = {157},
  number = {6},
  pages = {1237--1245},
  doi = {10.1016/j.jaci.2026.04.002}
}
Kostenlos starten →